Evidence for anti-VEGF treatment of diabetic macular edema

Ophthalmic Research

Volumn 48, Issue SUPPL. 1, 2012, Pages 16-20

  Bandello, F ^a   Berchicci, L ^a   La Spina, C ^a   Battaglia Parodi, M ^a   Iacono, P ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Anti vascular endothelial growth factor; Bevacizumab; Diabetic macular edema; Pegaptanib; Ranibizumab; VEGF Trap Eye

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR;

ARTICLE; CATARACT; CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865363759     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000339843     Document Type: Article

References (31)

1. Kempen JH, O'Colmain BJ, Leske MC, et al, Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-563. (Pubitemid 38456292)
2. Klein R: Retinopathy in a population-based study. Trans Am Ophthalmol Soc 1992; 90: 561-594. (Pubitemid 23048912)
3. Wild S, Roglic G, Green A, Sicree R, et al: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053. (Pubitemid 38579764)
4. Bandello F, Parodi MB, Lanzetta P, et al: Diabetic macular edema. Dev Ophthalmol 2010; 47: 73-110.
5. Neufeld G, Cohen T, Gengrinovitch S, et al: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
6. Grant MB, Afzal A, Spoerri P, et al: The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004; 13: 1275-1293. (Pubitemid 39359658)
7. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-848.
8. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
9. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487. (Pubitemid 24356306)
10. Gardner TW, Antonetti DA, Barber AJ, et al: Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(suppl 2): S253-S262. (Pubitemid 36351245)
11. Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, doublemasked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
12. Nguyen QD, Shah SM, Heier JS, et al, READ-2 Study Group: Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 2009; 116: 2175-2181.
13. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group: Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
14. Mitchell P, Bandello F, Schmidt-Erfurth U, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
15. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94: 761-774.
16. Elman MJ, Bressler NM, Qin H, et al: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network. Ophthalmology 2011; 118: 609-614.
17. Googe J, Brucker AJ, Bressler NM, et al: Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009-1027.
18. Bandello F, Cunha-Vaz J, Chong NV, et al: New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012; 26: 485-493.
19. Sultan MB, Zhou D, Loftus J, et al: A phase 2/3, multicenter, randomized, doublemasked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 2011; 118: 1107-1118.
20. Cunningham ET Jr, Adamis AP, Altaweel M, et al: Macugen Diabetic Retinopathy Study Group. A phase II randomized doublemasked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-1757.
21. Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.
22. Arevalo JF, Sanchez JG, Wu L, et al, Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488-1497.
23. Soheilian M, Ramezani A, Obudi A, et al: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-1150.
24. Soheilian M, Ramezani A, Yaseri M, et al: Initial macular thickness and response to treatment in diabetic macular edema. Retina 2011; 31: 1564-1573.
25. Lim JW, Lee HK, Shin MC: Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica 2012; 227: 100-106.
26. Goyal S, La Valley M, Subramanian ML: Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249: 15-27.
27. Economides AN, Carpenter LR, Rudge JS, et al: Cytokine traps: multi-component, highaffinity blockers of cytokine action. Nat Med 2003; 9: 47-52. (Pubitemid 36098259)
28. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393-11398. (Pubitemid 34920936)
29. Stewart MW, Rosenfeld PJ: Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-668. (Pubitemid 351684178)
30. Ohr M, Kaiser PK: Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012; 13: 585-591.
31. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al: The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118: 1819-1826.